Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
Patel SM, Morrow DA, Bellavia A, Berg DD, Bhatt DL, Jarolim P, Leiter LA, McGuire DK, Raz I, Steg PG, Wilding JPH, Sabatine MS, Wiviott SD, Braunwald E, Scirica BM, Bohula EA. Patel SM, et al. Among authors: mcguire dk. Eur J Heart Fail. 2024 Feb;26(2):260-269. doi: 10.1002/ejhf.3118. Epub 2024 Jan 4. Eur J Heart Fail. 2024. PMID: 38131261
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. Am Heart J. 2008 Nov;156(5):826-32. doi: 10.1016/j.ahj.2008.07.023. Epub 2008 Sep 2. Am Heart J. 2008. PMID: 19061694 Clinical Trial.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Free article. Clinical Trial.
Non-coronary peripheral arterial complications in people with type 2 diabetes: a Swedish retrospective cohort study.
Rawshani A, Eliasson B, Boren J, Sattar N, Bhatt D, El-Khalili L, Nordanstig J, Avdic T, Beckman JA, Gerstein HC, McGuire DK, Omerovic E, Rawshani A. Rawshani A, et al. Among authors: mcguire dk. Lancet Reg Health Eur. 2024 Mar 19;39:100888. doi: 10.1016/j.lanepe.2024.100888. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38803635 Free PMC article.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Free article. Clinical Trial.
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee. Chin CT, et al. Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022. Am Heart J. 2010. PMID: 20598967 Clinical Trial.
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators. Roe MT, et al. Among authors: mcguire dk. N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25. N Engl J Med. 2012. PMID: 22920930 Free article. Clinical Trial.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Hernandez AF, et al. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. Lancet. 2018. PMID: 30291013 Free article. Clinical Trial.
Non-coronary arterial outcomes in people with type 1 diabetes mellitus: a Swedish retrospective cohort study.
Avdic T, Eliasson B, Rawshani A, Boren J, Gerstein HC, Nordanstig J, Rihawi M, Beckman JA, McGuire DK, Omerovic E, Sattar N, Bhatt DL, Rawshani A. Avdic T, et al. Among authors: mcguire dk. Lancet Reg Health Eur. 2024 Feb 15;39:100852. doi: 10.1016/j.lanepe.2024.100852. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38803631 Free PMC article.
What the SELECT trial of semaglutide means for clinicians.
Sattar N, Lee MMY, McGuire DK. Sattar N, et al. Among authors: mcguire dk. Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03013-7. Online ahead of print. Nat Med. 2024. PMID: 38796654 No abstract available.
475 results